On September 28, 2023 TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, reported that it is bringing BNCT to this year’s annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego (Press release, TAE Life Sciences, SEP 28, 2023, View Source [SID1234635502]). The company is set to revolutionize the way attendees perceive BNCT with an immersive Augmented Reality (AR) experience that offers an in-depth look at the future of cancer treatments, informative talks about the state of BNCT, and a variety of captivating exhibits.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TAE Life Sciences Brings BNCT to ASTRO
The AR experience at the TAE Life Sciences booth will offer visitors a captivating journey into the world of BNCT, featuring:
● A virtual tour of the Alphabeam system, showcasing the clinical workflow of BNCT and illustrating the inner workings of this revolutionary technology.
● Insights into the setup of a BNCT system, including details on building requirements, layout, and the treatment process.
"We’re on the verge of redefining how the world treats cancer and ASTRO is the perfect venue to showcase the capabilities of our Alphabeam BNCT system. We’re not just showing a glimpse of our technology at the show; we’re sharing a vision for a future where cancer is treated with unprecedented precision. We hope that the immersive experience we’re bringing to the show ignites a spark of hope in the hearts of attendees, and together, we can work towards a brighter future for cancer patients," said Rob Hill, CEO at TAE Life Sciences.
TAE Life Sciences will host a presentation, titled "Reimagining BNCT for Biologically Targeted Radiation Therapy," at its booth stage on October 1 at 11:00 AM. Featuring talks from Rob Hill, CEO of TAE Life Sciences, Minesh Mehta, MD, from Miami Cancer Institute, and Sandro Rossi, General Manager and Technical Director at CNAO, this presentation will include updates on the global progress of BNCT, preclinical and clinical results, and insight into the treatment’s profound significance in shaping the future of cancer treatment.
Presentation Details:
Who: Robert Hill, CEO at TAE Life Sciences; Minesh Mehta, Chief of Radiation Oncology at Miami Cancer Institute; Sandro Rossi, General Manager at CNAO
What: Presentation: Reimagining BNCT for Biologically Targeted Radiation Therapy When: October 1, 2023 at 11:00 AM
Where: San Diego Convention Center, Booth 3732
Sandro Rossi from CNAO shared his enthusiasm, stating, "Our collaboration with TAE Life Sciences marks a significant step forward in BNCT and brings an exciting addition to Europe’s first Hadrontherapy center. By incorporating BNCT into our comprehensive treatment offerings, we are expanding the horizons of radiation therapy to treat metastatic cancers. This groundbreaking approach has the potential to redefine how we combat cancer, making treatments more effective and tailored to each patient’s unique needs. Together with TAE Life Sciences, we are not just advancing technology; we are advancing the future of cancer care in Europe and beyond."
At ASTRO, TAE Life Sciences will have several exciting exhibits on display in its booth, including:
● BNCT treatment planning demonstration featuring TAE Life Sciences’ proprietary dose engine running on the Raysearch treatment planning engine.
● Details about TAE Life Sciences’ innovative BNCT drug development program, showcasing the latest advancements in its antibody boron conjugate (ABC) drugs as well as pre-clinical data.
● A compelling poster comparing treatment planning outcomes with TAE Life Sciences’ Boronotyrosine (BTS) drug versus Boronophenylalanine (BPA), shedding light on the significant advantages of BTS in boron delivery for BNCT interventions.
Minesh Mehta, representing Miami Cancer Institute, passionately emphasized the importance of accelerating BNCT research in the United States, stating, "Collaborations like the one between TAE Life Sciences and CNAO are essential to advancing cancer care. The opportunity for BNCT is burgeoning, especially with the increasing availability of antibody-drug conjugates (ADCs). Currently, there are a dozen or more ADCs that can be harnessed for boron conjugation. Fast-tracking BNCT research in the USA is not just a priority; it’s an urgent necessity. We must seize this moment to bring BNCT to the forefront of modern cancer treatment and offer new hope to patients across the nation and beyond."
For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit www.taelifesciences.com.